Michael E. Steffey

Biochemistry, Genetics and Molecular Biology · Life Sciences

15h-index1.2kcitations33works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(12), HER2/EGFR in Cancer Research(9), Protein Kinase Regulation and GTPase Signaling(8), Receptor Mechanisms and Signaling(5), Synthesis and biological activity(4)

Publications33 total

Supplementary Table S1 from UM-164: A Potent c-Src/p38 Kinase Inhibitor with <i>In Vivo</i> Activity against Triple-Negative Breast Cancer
2023Open Access
Data from UM-164: A Potent c-Src/p38 Kinase Inhibitor with <i>In Vivo</i> Activity against Triple-Negative Breast Cancer
2023Open Access
Supplementary Materials and Methods from UM-164: A Potent c-Src/p38 Kinase Inhibitor with <i>In Vivo</i> Activity against Triple-Negative Breast Cancer
2023Open Access
Supplementary Figure Legends from UM-164: A Potent c-Src/p38 Kinase Inhibitor with <i>In Vivo</i> Activity against Triple-Negative Breast Cancer
2023Open Access
Supplementary Figure Legends from UM-164: A Potent c-Src/p38 Kinase Inhibitor with <i>In Vivo</i> Activity against Triple-Negative Breast Cancer
2023Open Access
Data from UM-164: A Potent c-Src/p38 Kinase Inhibitor with <i>In Vivo</i> Activity against Triple-Negative Breast Cancer
2023Open Access
Supplementary Table S1 from UM-164: A Potent c-Src/p38 Kinase Inhibitor with <i>In Vivo</i> Activity against Triple-Negative Breast Cancer
2023Open Access
Supplementary Figures S1-S12 from UM-164: A Potent c-Src/p38 Kinase Inhibitor with <i>In Vivo</i> Activity against Triple-Negative Breast Cancer
2023Open Access
Supplementary Figures S1-S12 from UM-164: A Potent c-Src/p38 Kinase Inhibitor with <i>In Vivo</i> Activity against Triple-Negative Breast Cancer
2023Open Access
Supplementary Materials and Methods from UM-164: A Potent c-Src/p38 Kinase Inhibitor with <i>In Vivo</i> Activity against Triple-Negative Breast Cancer
2023Open Access
Abstract 2643: Human and mouse reconstructed plate-based 3-dimensional culture assays that mimic the tumor microenvironment
Cancer Research·2021
Retraction: UM-164: A Potent c-Src/p38 Kinase Inhibitor with <i>In Vivo</i> Activity against Triple-Negative Breast Cancer
Clinical Cancer Research·2020· 2 cited
UM-164: A Potent c-Src/p38 Kinase Inhibitor with <i>In Vivo</i> Activity against Triple-Negative Breast Cancer
Clinical Cancer Research·2016· 27 cited
Abstract 5536: KB-164, a novel and highly potent Src family kinase inhibitor, reduces cancer cell invasion and abrogates downstream oncogenic pathways in triple negative breast cancer
Cancer Research·2015
Discovery of Bivalent Kinase Inhibitors via Enzyme-Templated Fragment Elaboration
ACS Medicinal Chemistry Letters·2015· 16 citedOpen Access
Exquisitely Specific Bisubstrate Inhibitors of c-Src Kinase
ACS Chemical Biology·2015· 27 citedOpen Access
Substrate Activity Screening with Kinases: Discovery of Small‐Molecule Substrate‐Competitive c‐Src Inhibitors
Angewandte Chemie International Edition·2014· 22 citedOpen Access
Substrate Activity Screening with Kinases: Discovery of Small‐Molecule Substrate‐Competitive c‐Src Inhibitors
Angewandte Chemie·2014· 4 citedOpen Access
Development of a Chimeric c-Src Kinase and HDAC Inhibitor
ACS Medicinal Chemistry Letters·2013· 46 citedOpen Access
Irreversible Inhibitors of c-Src Kinase That Target a Nonconserved Cysteine
ACS Chemical Biology·2012· 44 cited
page 1 of 2Next →

Frequent Co-authors

Matthew B. Soellner(20), Kristoffer Brandvold(16), Frank E. Kwarcinski(16), Eric J. Lachacz(15), Rabia A. Gilani(13), Sameer Phadke(13), Li Bao(13), Sofía D. Merajver(13), Michele Dziubinski(12), Kelley M. Kidwell(12), Carrie R. Graveel(10), Robert G. MacKenzie(6), Christel C. Fox(5), Edward F. Nemeth(4), Arlene M. Manelli(3), John Fox(3), Ronald W. Barrett(3), Meghan E. Breen(3), Nancy J. Pollock(2), D E Frail(2)